Bradley Pharmaceuticals Completes 400,000 Share Buyback; Board of Directors Authorizes Additional 600,000 Shares; Cumulative Repurchase Up to 12% of Total Shares.

FAIRFIELD, N.J.--(BUSINESS WIRE)--Jan. 5, 1999--BRADLEY PHARMACEUTICALS, INC. (NASDAQ NMS: BPRX) reported today that it has completed a program previously announced to repurchase 400,000 shares, in open market transactions, during the previous 24 months. In addition, Bradley Pharmaceuticals' Board of Directors has authorized an additional 600,000 shares to be repurchased, in open market transactions, over the next 36 months.

The total authorized repurchase of 1 million shares will amount to approximately 12% of the current shares outstanding. These BRADLEY shares will be held in treasury by the Company and used for purposes deemed necessary by the Bradley Board of Directors, including funding the Company's 401(k) Plan.

Daniel Glassman, Chairman and CEO of Bradley Pharmaceuticals, stated, "This Stock Repurchase Plan underscores our commitment towards increasing shareholder value. 1998 will mark the Third Consecutive Profitable Year for Bradley Pharmaceuticals--an achievement all of us are very proud of. We are very excited to continue to execute our strategy focused on the acquisition and subsequent life cycle management of non-strategic pharmaceutical products. With operations solid, our marketing and promotional efforts reaping success and our total field sales personnel approaching 70 people, and plans to internally fund expansion to 100 strong, the management team is looking forward to 1999 and beyond."

BRADLEY PHARMACEUTICALS, INC. manufactures and markets brandname products and over-the-counter pharmaceuticals and health-related products throughout the United States as well as in more than 25 international markets. Bradley Common A Shares (BPRX) are traded on the NASDAQ National Market System.

Please visit our website at www.bradpharm.com

This release may contain forward-looking statements which reflect management's current views of future events and operations. These forward-looking statements are based on assumptions and external factors, including assumptions relating to regulatory action, capital requirements and competing products. Any changes in such assumptions are external factors and could produce significantly different results.